Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADK | P55263 | 2/20 | 0.40 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.40 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13598781 | 0.89 | ADORA2A (0.55) | ADORA2APRMT5WDR77ADORA3 | |
| SCHEMBL4430217 | 0.89 | ADORA2A (0.55) | ADORA2APRMT5WDR77ADORA3 | |
| SCHEMBL1738408 | 0.89 | ADORA2A (0.55) | ADORA2APRMT5WDR77ADORA3 | |
| SCHEMBL13598733 | 0.89 | ADORA2A (0.55) | ADORA2APRMT5WDR77ADORA3 | |
| SCHEMBL12150825 | 0.86 | ADK (0.53) | ADORA2APRMT5WDR77ADKMETTL3 | |
| SCHEMBL12300523 | 0.86 | ADK (0.53) | ADORA2APRMT5WDR77ADKMETTL3 | |
| SCHEMBL733393 | 0.86 | ADK (0.53) | ADORA2APRMT5WDR77ADKMETTL3 | |
| SCHEMBL12154832 | 0.86 | ADK (0.53) | ADORA2APRMT5WDR77ADKMETTL3 | |
| SCHEMBL14640021 | 0.86 | ADK (0.53) | ADORA2APRMT5WDR77ADKMETTL3 | |
| SCHEMBL3232370 | 0.86 | ADORA2A (0.39) | ADORA2APRMT5WDR77ADKMETTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309412-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | IONIS PHARMACEUTICALS, INC. | 2014-10-16 | — | — | US | disclosed |
| US-8481712-B2 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME CORP. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120165515-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2012-06-28 | — | — | US | disclosed |
| EP-2399588-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | Merck Sharp & Dohme Corp. (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-2360166-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | Merck Sharp & Dohme Corp. (US) | 2011-08-24 | — | — | EP | disclosed |
| US-7323453-B2 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | MERCK & CO., INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-20070275912-A1 | Nucleoside derivatives as inhibitors of rna-dependent RNA viral polymerase | MERCK SHARP & DOHME CORP. | 2007-11-29 | — | — | US | disclosed |
| US-7202224-B2 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK & CO., INC. (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1355916-B1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | MERCK & CO INC (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20060264390-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | IONIS PHARMACEUTICALS, INC. | 2006-11-23 | — | — | US | disclosed |
| US-20060205686-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | BHAT BALKRISHEN | 2006-09-14 | — | — | US | disclosed |
| US-7105499-B2 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK & CO., INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-20050164960-A1 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | MERCK SHARP & DOHME CORP. | 2005-07-28 | — | — | US | disclosed |
| US-6777395-B2 | VIRICIDES | MERCK & CO., INC. | 2004-08-17 | — | — | US | disclosed |
| US-20040110717-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | MERCK SHARP & DOHME LLC | 2004-06-10 | — | — | US | disclosed |
| US-20040072788-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | BHAT BALKRISHEN (US) | 2004-04-15 | — | — | US | disclosed |
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2004-04-08 | — | — | US | disclosed |
| US-20040014957-A1 | Oligonucleotides having modified nucleoside units | ISIS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| US-20040014108-A1 | Oligonucleotides having modified nucleoside units | ISIS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| US-20020147160-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADORA2A 416/4885PRMT5 436/4885WDR77 1478/4885 |
| US-20040014108-A1 | Oligonucleotides having modified nucleoside units | RNASEH1, RNASE1, RNASEL | ADORA2A 1134/4885PRMT5 2966/4885WDR77 1841/4885 |
| US-20040014957-A1 | Oligonucleotides having modified nucleoside units | RNASE1, RNASEH1, RNASEL | ADORA2A 813/4885PRMT5 3154/4885WDR77 1648/4885 |
| US-20040110717-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | NSUN2, NSUN3, POLRMT | ADORA2A 395/4885PRMT5 352/4885WDR77 1658/4885 |
| US-20060264390-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADORA2A 416/4885PRMT5 436/4885WDR77 1478/4885 |
| US-20040072788-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADORA2A 416/4885PRMT5 436/4885WDR77 1478/4885 |
| US-20140309412-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | NSUN2, NSUN3, POLRMT | ADORA2A 416/4885PRMT5 436/4885WDR77 1478/4885 |
| US-20020147160-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADORA2A 416/4885PRMT5 436/4885WDR77 1478/4885 |
| US-20120165515-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADORA2A 416/4885PRMT5 436/4885WDR77 1478/4885 |
| US-20060205686-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADORA2A 416/4885PRMT5 436/4885WDR77 1478/4885 |
| US-20070275912-A1 | Nucleoside derivatives as inhibitors of rna-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADORA2A 416/4885PRMT5 436/4885WDR77 1478/4885 |
| US-20050164960-A1 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | ITPA, PNP, NUDT1 | ADORA2A 192/4885PRMT5 1470/4885WDR77 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.